Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.28 and traded as low as $0.94. Spero Therapeutics shares last traded at $1.03, with a volume of 330,176 shares trading hands.
Analyst Ratings Changes
A number of analysts have commented on the company. HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Spero Therapeutics in a report on Monday, December 2nd. Cantor Fitzgerald reiterated an "overweight" rating on shares of Spero Therapeutics in a report on Friday, November 15th. Evercore ISI cut Spero Therapeutics from an "outperform" rating to an "in-line" rating and set a $5.00 price objective on the stock. in a research note on Friday, December 20th. Finally, TD Cowen reiterated a "hold" rating on shares of Spero Therapeutics in a research note on Monday, November 18th.
Check Out Our Latest Stock Report on SPRO
Spero Therapeutics Price Performance
The company has a market capitalization of $56.15 million, a P/E ratio of 14.72 and a beta of 0.59. The firm has a fifty day moving average price of $1.17 and a 200-day moving average price of $1.27.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Spero Therapeutics stock. Renaissance Technologies LLC boosted its stake in shares of Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) by 14.2% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 975,952 shares of the company's stock after buying an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned approximately 1.81% of Spero Therapeutics worth $1,269,000 as of its most recent SEC filing. 25.60% of the stock is owned by institutional investors.
About Spero Therapeutics
(
Get Free Report)
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.
Further Reading
Before you consider Spero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.
While Spero Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
